Menopause treatments

In women with an intact uterus for the treatment of moderate to severe vasomotor symptoms associated with menopause treatment of vulval and vaginal atrophy Femhrt and CHmaraPro excluded) osteoporosis prevention CombiPatch and ClimaraPro excluded) treatment of hypoestrogenism caused by hypogonadism, castration, or primary ovarian failure CombiPatch only). 

Menopause Treatment with hormonal contraceptives may mask the onset of the climacteric. 

It is indicated in the management of moderate to severe vasomotor symptoms associated with menopause treatment of atrophic vaginitis, kraurosis vulvae, fanale hypogonadism, symptoms of female castration, and primary ovarian failure prevention and treatment of osteoporosis (conjugated estrogens) palliative treatment of metastatic breast or prostate cancer in selected women and men treatment of postpartum breast engorgement and abnormal uterine bleeding. 

The combination is indicated in the treatment of moderate to severe vasomotor symptoms associated with menopause treatment of vulval and vaginal atrophy and osteoporosis prevention. 

C,flH2o02- White crystals, m.p. 168-171 °C. Prepared from deoxyanisoin by ethylation, conversion to the alcohol, dehydration and demethylation. It is an oestrogenic substance which is highly active when administered orally. It is used for treating menopausal symptoms, for the suppression of lactation and for treatment of cancer of the prostate. 

ERT is a clinical treatment whereby premenopausal estrogen levels are restored and the symptoms of menopause are relieved. 

M ale and female hormones play a vital role because they aid in development and maintenance of secondary sex characteristics and are necessary for human reproduction. Although hormones are naturally produced by die body, administration of a male or female hormone may be indicated in the treatment of certain disorders, such as inoperable breast cancer, male hypogonadism, and male or female hormone deficiency. Hormones also are used as contraceptives and for treating the symptoms of menopause... 

Many women seek medical treatment for the relief of menopausal symptoms, primarily hot flashes however, the role of hormone-replacement therapy (HRT) has changed dramatically over the years. HRT has long been prescribed for relief of menopausal symptoms and, until recent years, has been purported to protect women from CHD. The original reason behind recommending HRT in postmenopausal women revolved around a simple theory If the hormones lost during menopause were replaced through drug therapy, women would be protected from both menopausal symptoms and chronic diseases that often follow after a woman experiences menopause. Recent studies have disproved this theory. 

Vasomotor symptoms, as well as other menopausal symptoms, occur in over 50% of perimenopausal women and over 80% of menopausal women.5 Menopausal symptoms tend to be more severe in women who undergo surgical menopause compared with natural menopause because of the more rapid decline in estrogen concentrations. Women who seek medical treatment should undergo laboratory evaluation to rule out other conditions that may present with similar symptoms, such as abnormal thyroid function or pituitary adenoma. Once other conditions have been excluded, HRT should be considered. 

Hormone-replacement therapy remains the most effective treatment for vasomotor symptoms and vulvovaginal atrophy and should be considered for women experiencing these symptoms. The goals of treatment are to alleviate or reduce menopausal symptoms and to improve the patient s quality of life while minimizing adverse effects of therapy. The appropriate route of administration should be chosen based on individual patient symptoms and should be continued at the lowest dose for the shortest duration consistent with treatment goals for each patient. 

Estrogen currently is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause. In addition, it is indicated for the prevention of postmenopausal osteoporosis in women with significant risk however, it is recommended that non-estrogen medications receive consideration for long-term use. Oral or transdermal estrogen products should be prescribed at the lowest... 

---